EGR1 and myocardial ischemia: This can also include DNAzymes targeting EGR1, which have been used by ourselves and others in a range of local delivery models to reduce post-angioplasty restenosis (53, 54, 85), in-stent restenosis (54) and to lower infarct size following myocardial ischemia-reperfusion (86, 87).